Amgen (NASDAQ:AMGN) initiated with Neutral rating at Guggenheim.
Interpace Biosciences (NASDAQ:IDXG) initiated with Buy rating at Janney Montgomery.
Intersect ENT (NASDAQ:XENT) downgraded to Underperform with a $10 (2% downside risk) price target at Bank of America.
Organigram (OGI CN) downgraded to Neutral with a C$2.75 (24% upside) price target at CIBC. Shares in U.S. (NASDAQ:OGI) up 3% premarket.
https://seekingalpha.com/news/3560770-guggenheim-on-fence-amgen-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.